More importantly, using both HCT116-WT and HCT116-p53−/− cell lines, as shown in Fig. 2E, 2F, the CRC xenograft tumor growth was clearly impaired in HCT116-WT cells, but not in HCT116-p53−/− cells, in vivo when CBX8 was stably knocked down in these cells, reinforcing the notion that the inhibition of CBX8 knockdown on cell growth mainly relies on p53 in CRC cells. The gene discussed is TP53; the disease is colorectal carcinoma.